Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Accurate diagnosis and evaluation are the cornerstones of effective treatment for acute lymphocytic leukemia (ALL), a rapidly progressing blood cancer that primarily affects lymphoid progenitor cells. International patients seeking specialized hematology care rely on clear, evidence‑based pathways to understand their disease and make informed decisions. In this guide we walk through every step of the diagnostic journey—from the first clinical encounter to the multidisciplinary review that shapes the therapeutic plan—while highlighting the advanced resources available at Liv Hospital.
Globally, ALL accounts for roughly 20% of childhood leukemias and 5% of adult cases, yet survival rates have improved dramatically thanks to precise diagnostic techniques and targeted therapies. By integrating modern laboratory methods, high‑resolution imaging, and molecular profiling, clinicians can stratify risk, predict response, and personalize treatment. This page is designed for patients, families, and referring physicians who need a comprehensive overview of what to expect when undergoing ALL assessment at a JCI‑accredited center.
The diagnostic pathway begins with a thorough clinical assessment performed by a hematology specialist. During this visit the physician gathers a detailed medical history, evaluates presenting symptoms, and conducts a focused physical examination.
These observations guide the selection of subsequent laboratory and imaging studies. At Liv Hospital, clinicians use standardized assessment forms to ensure no detail is overlooked, facilitating a seamless transition to the next diagnostic phase.
Blood analysis provides the first objective evidence of leukemic activity. A complete blood count (CBC) with differential is essential, often revealing characteristic abnormalities.
Additional blood tests include:
All samples are processed in Liv Hospital’s accredited laboratory, ensuring rapid turnaround and high analytical accuracy. The results not only confirm suspicion of ALL but also help gauge the urgency of further invasive procedures.
The definitive diagnosis of ALL rests on bone marrow aspiration and biopsy. This procedure provides cellular material for morphological, immunophenotypic, and genetic analyses.
The integration of these data points completes the diagnosis and evaluation process, allowing physicians to assign a risk category and select an appropriate therapeutic protocol. Liv Hospital’s hematopathology team follows international standards, providing detailed reports within 48–72 hours.
While blood and marrow studies define the disease at the cellular level, imaging determines the extent of extramedullary involvement and guides treatment planning.
All imaging studies are coordinated by Liv Hospital’s radiology department, which utilizes state‑of‑the‑art equipment and radiologists specialized in oncologic imaging. The resulting reports are integrated into the multidisciplinary case discussion.
Modern ALL management depends heavily on the molecular landscape of the leukemia cells. Targeted therapies are available for specific genetic alterations, making comprehensive profiling indispensable.
Liv Hospital’s molecular diagnostics laboratory follows ISO‑15189 standards, ensuring that every result is accurate, reproducible, and delivered promptly. The data feed directly into the multidisciplinary tumor board, where therapeutic options are matched to the patient’s molecular signature.
After completing the full spectrum of tests, the case is presented to a multidisciplinary team (MDT) that includes hematologists, pathologists, radiologists, transplant physicians, and supportive‑care specialists. This collaborative review synthesizes the diagnosis and evaluation findings into a personalized treatment roadmap.
Each recommendation is discussed with the patient and their family, taking into account cultural preferences, travel logistics, and financial considerations. Liv Hospital’s International Patient Services team assists with visa arrangements, interpreter provision, and accommodation, ensuring that the transition from diagnosis to therapy is smooth and stress‑free.
Liv Hospital combines JCI accreditation, a dedicated hematology department, and a comprehensive international patient program. Our experts have extensive experience treating acute lymphocytic leukemia across all age groups, and our facilities include cutting‑edge laboratories, advanced imaging suites, and a supportive multidisciplinary network. International patients benefit from coordinated logistics, multilingual staff, and personalized care plans that begin the moment the diagnosis is confirmed.
Ready to take the next step in your leukemia journey? Contact Liv Hospital’s International Patient Services today to schedule a virtual consultation, arrange travel, and start a personalized treatment plan backed by world‑class expertise.
Send us all your questions or requests, and our expert team will assist you.
During the initial visit, the physician records symptoms such as fatigue, fever, bruising, and weight loss, and asks about prior infections, family history, and exposures to radiation or toxins. A focused physical exam looks for pallor, jaundice, lymphadenopathy, hepatosplenomegaly, and bleeding signs. These findings guide the selection of laboratory and imaging studies that follow, ensuring a systematic approach to confirming ALL.
The CBC often shows abnormal white blood cell counts (high or low), anemia, and thrombocytopenia. A peripheral blast count greater than 20% meets the WHO diagnostic threshold for leukemia. Additional labs such as liver and kidney function panels, elevated lactate dehydrogenase (reflecting tumor turnover), and coagulation studies help assess disease burden and risk of complications like disseminated intravascular coagulation.
The patient lies in a lateral decubitus or supine position while a needle is inserted into the posterior iliac crest after local anesthetic. Aspirate and core biopsy provide material for light microscopy (identifying lymphoblasts), flow cytometry (detecting CD10, CD19, CD34, TdT), karyotyping (showing translocations like t(9;22)), and molecular assays such as FISH or PCR for specific gene rearrangements. These results confirm ALL and define its genetic risk profile.
Initial staging often includes a chest X‑ray to detect mediastinal widening (common in T‑cell ALL) and abdominal ultrasound for liver, spleen, and lymph node enlargement. CT scans provide detailed cross‑sectional images of thoracic, abdominal, and pelvic regions. MRI is preferred for central nervous system evaluation, while PET‑CT identifies metabolically active disease sites, especially in relapsed or refractory cases. The imaging findings are integrated with laboratory data to determine disease stage.
Next‑generation sequencing, multiplex PCR, and aCGH reveal mutations, fusion transcripts, and copy‑number changes. For example, Philadelphia chromosome‑positive ALL benefits from tyrosine‑kinase inhibitors (e.g., imatinib) combined with chemotherapy. MLL‑rearranged disease often requires intensified regimens and may prompt early consideration of stem‑cell transplantation. Conversely, low‑risk genetic profiles allow for reduced‑intensity protocols, minimizing toxicity while maintaining cure rates.
Your Comparison List (you must select at least 2 packages)
